Cotización Prelude Therapeutics - PRLD

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

2.5442

Postura de Compra

2.30

Postura de Venta

4.00

Volume Operado de la Acción

469,059

2.4501 Rango del Día 2.67

1.66 Rango de 52 semanas 6.80

Capitalización de Mercado [m]

139.993M

Precio Anterior

2.55

Precio de Apertura

2.55

Hora

2.57

Última hora de negociación

Volumen financiero

US$ 1,197,886

Precio Promedio Ponderado

2.5538

Volumen promedio (3 m)

273,949

Acciones en circulación

55,024,470

Rendimiento del Dividendo

Ratio Precio/Utilidad

-1.15

Beneficio por acción (BPA)

-2.21

turnover

Beneficio neto

-121.83M

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.preludetx.com

Sede

Wilmington, Delaware, USA

Fundado

Prelude Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRLD. The last closing price for Prelude Therapeutics was US$2.55. Over the last year, Prelude Therapeutics shares have traded in a share price range of US$ 1.66 to US$ 6.80.

Prelude Therapeutics currently has 55,024,470 shares in issue. The market capitalisation of Prelude Therapeutics is US$140.31 million. Prelude Therapeutics has a price to earnings ratio (PE ratio) of -1.15.

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...

Form 8-K - Current report

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-2.3558	-48.0775510204	4.9	5.075	2.4	1075136	2.64114257	CS
4	-3.1358	-55.2077464789	5.68	5.945	2.4	492264	3.70356169	CS
12	-1.2358	-32.6931216931	3.78	6.8	2.4	273949	4.36563433	CS
26	-2.3958	-48.4979757085	4.94	6.8	2.4	146795	4.32553707	CS
52	-0.5658	-18.192926045	3.11	6.8	1.66	148352	3.71951161	CS
156	-31.8658	-92.6062191223	34.41	36.95	1.66	182886	9.14886073	CS
260	-23.2158	-90.123447205	25.76	95.375	1.66	190625	19.24308852	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BNZIBanzai International Inc	US$ 5.645 (96.01%)	61.39M
ZJYLJin Medical International Ltd	US$ 3.975 (50.00%)	1.24M
ANEBAnebulo Pharmaceuticals Inc	US$ 2.9001 (39.43%)	78.85k
XPONExpion360 Inc	US$ 0.081 (39.18%)	1.46B
AENTAlliance Entertainment Holding Corporation	US$ 2.74 (34.31%)	4.23M
GSIWGarden Stage Ltd	US$ 1.34 (-82.89%)	26.44M
CRBPCorbus Pharmaceuticals Holdings Inc	US$ 19.51 (-62.26%)	12.29M
LGCBLinkage Global Inc	US$ 0.4183 (-57.70%)	2.16M
BFIBurgerFi International Inc	US$ 0.0855 (-42.27%)	15.05M
SKYESkye Bioscience Inc	US$ 3.17 (-42.26%)	5.14M
XPONExpion360 Inc	US$ 0.081 (39.18%)	1.46B
NVDANVIDIA Corporation	US$ 116.00 (-1.59%)	377.84M
AAPLApple Inc	US$ 228.20 (-0.29%)	320.78M
INTCIntel Corporation	US$ 21.84 (3.31%)	261.68M
VERBVerb Technology Company Inc	US$ 0.0742 (33.45%)	178.65M